New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan

• Takeda has submitted an application for a single pack for the first eradication of Helicobacter pylori. It contains three drugs, namely, TAKECAB^® — developed by Takeda for treating acid-related disease—amoxicillin, and clarithromycin, as well as a single pack for the second eradication of Helicobacter pylori containing three drugs: TAKECAB^®, amoxicillin, and metronidazole.
• Takeda and Otsuka executed an agreement at the end of March 2014 to co-promote TAKECAB^® (for treating acid-related diseases) in Japan. Under the agreement, the two companies will conduct informational activities about a single pack for the eradication of Helicobacter pylori for healthcare professionals after approval of it and address unmet clinical needs in the treatment of acid-related diseases.
• Otsuka will receive co-promotion fees from Takeda based on sales of TAKECAB^® and the single pack containing TAKECAB^® (in accordance with conditions specified in the agreement).

Osaka and Tokyo, Japan, March 26, 2015—Takeda Pharmaceutical Company Limited (Head office: Chuo-ku, Osaka; President and COO: Christophe Weber; “Takeda”) and Otsuka Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Tatsuo Higuchi; “Otsuka”) announced today that Takeda submitted a new drug application to the Ministry of Health, Labour and Welfare for a single pack containing drugs which is the eradication of the Helicobacter Pylori(“H. pylori”). These drugs are available in the form of a single pack. One pack contains three drugs for the first eradication of H. pylori, namely, TAKECAB^® (generic name:　Vonoprazan fumarate, hereinafter “TAKECAB”) — developed by Takeda for treating acid-related diseases through a novel mechanism of action using potassium-competitive acid blockers (P-CABs) — amoxicillin (Japanese brand name: AMOLIN^®), and clarithromycin (Japanese brand name: Clarith^®). Another contains three drugs for the second　eradication of H. pylori, namely, TAKECAB, amoxicillin , and metronidazole (Japanese brand name: Flagyl^®).

TAKECAB was launched in Japan on February 26 this year. The eradication of H. pylori for “Gastric ulcer, duodenal ulcer, gastric mucosa-associated lymphatic tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, gastric diseases after endoscopic resection of early stage gastric cancer, and H. pylori gastritis” are approved as well.

Each blister card has the daily dose of the single pack containing two antibacterial drugs and TAKECAB for the treatment of H. pylori eradication. The packaging helps improve the medication adherence of patients. By ensuring that patients follow the dosage and administration of each drug used for the treatment of H. pylori eradication, the effectiveness of the treatment is expected to improve further. In addition, we consider that this will also increase the convenience of healthcare professionals, helping us contribute further to the treatment of eradication in Japan. 

Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a global research-based company focusing mainly on pharmaceuticals. As the largest pharmaceutical company in Japan and a global leader in the industry, Takeda is committed to improving the health of people worldwide as a leading innovator in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

Otsuka Pharmaceutical Company, Limited
Otsuka is a global healthcare company with the corporate philosophy: “Otsuka – people creating new products for better health worldwide.” Otsuka researches, develops, manufactures, and markets innovative and original products, focusing on pharmaceutical products for treating diseases and nutraceutical products to maintain everyday health. Otsuka invites you to visit its global website at www.otsuka.co.jp/en.